Priming of microglia by type II interferon is lasting and resistant to modulation by interleukin-10 in situ

Immunological priming by type II interferon (IFN-γ) is crucial for evoking neurotoxic phenotypes of microglia (tissue-resident macrophages). We report that serial exposure of hippocampal slice cultures to IFN-γ and lipopolysaccharide (Toll-like receptor 4 ligand) induces high release of IL-6, TNF-α...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hemmerich, Marc (VerfasserIn) , Malorny, Nikolai (VerfasserIn) , Lewen, Andrea (VerfasserIn) , Hollnagel, Jan-Oliver (VerfasserIn) , Chausse de Freitas, Bruno (VerfasserIn) , Kann, Oliver (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 28 April 2022
In: Journal of neuroimmunology
Year: 2022, Jahrgang: 368, Pages: 1-10
ISSN:1872-8421
DOI:10.1016/j.jneuroim.2022.577881
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jneuroim.2022.577881
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0165572822000765
Volltext
Verfasserangaben:Marc Hemmerich, Nikolai Malorny, Andrea Lewen, Jan-Oliver Hollnagel, Bruno Chausse, Oliver Kann
Beschreibung
Zusammenfassung:Immunological priming by type II interferon (IFN-γ) is crucial for evoking neurotoxic phenotypes of microglia (tissue-resident macrophages). We report that serial exposure of hippocampal slice cultures to IFN-γ and lipopolysaccharide (Toll-like receptor 4 ligand) induces high release of IL-6, TNF-α and nitric oxide, concomitant loss of electrical network activity (neuronal gamma oscillations) and neurodegeneration. Notably, these effects are still present after 3 days of IFN-γ removal but neither mimicked by IFN-α nor attenuated by anti-inflammatory cytokine, IL-10. Our findings might be relevant for brain diseases featuring elevated IFN-γ levels, such as viral and bacterial infections, multiple sclerosis and Alzheimer's disease.
Beschreibung:Gesehen am 21.06.2022
Beschreibung:Online Resource
ISSN:1872-8421
DOI:10.1016/j.jneuroim.2022.577881